Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

Montefiore Medical Center14 enrolled

Overview

This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.

Night time bedwetting is a common complication of sickle cell disease, and affects up to 30 % of children . Desmopressin is an oral medication that increases water reabsorption in the kidneys. Studies have shown that it is effective in decreasing bedwetting episodes in children without sickle cell disease. Chronic sickling episodes causing damage to the kidneys could cause permanent damage and may make this treatment ineffective in sickle cell disease. This trial will inform pediatric sickle cell doctors if desmopressin is an appropriate treatment for bed wetting in the investigators patients. This work is being continued on study ID: 2020-11268.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Nocturnal Enuresis Anemia, Sickle Cell

Interventions

DesmopressinDRUG

Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement

Eligibility

Sex: ALLMin age: 8 YearsMax age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with Hemoglobin SS, SC, SB0thal or SB+thal 2. Patients with at least two episodes of primary nocturnal enuresis per week or four episodes over the two weeks prior to enrollment. 3. Patients with secondary enuresis who have been evaluated and cleared by a pediatric urologist as not having other etiologies of enuresis (e.g. overactive detrusor activity, a genitourinary anatomic abnormality) Exclusion Criteria: 1. Patients with developmental delay or neurologic dysfunction secondary to stroke. 2. Patients with hypertension or underlying renal disease. 3. Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing normal genitourinary anatomy is sufficient to clear a patient for the study. 4. Patients with daytime urinary incontinence 5. Patients with glucosuria on urinalysis. 6. Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric urologist to rule out other etiologies of enuresis. 7. Patients who are pregnant. 8. Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).

Locations (1)

Children's Hospital at Montefiore

The Bronx, New York, United States

Outcomes

Primary Outcomes

Reduction in Bedwetting episodes

To prospectively assess if the use of desmopressin in patients with sickle cell disease and nocturnal enuresis will decrease the number of nighttime episodes of enuresis by 50% after initiating DDAVP at 0.4 mg nightly dose with dose escalation as clinically indicated compared to the control group.

Time frame: Baseline and 4 weeks

Secondary Outcomes

Quality of life measure

To determine if patients with sickle cell disease and nocturnal enuresis receiving desmopressin will have an improved quality of life compared to the control group.

Time frame: Baseline and 4 weeks

Reduction in Nighttime awakenings

To determine if the use of desmopressin in patients with nocturnal enuresis improves rates of nocturia, defined as episodes of nighttime awakening to void in children ≥5 years of age, compared to the control group.

Time frame: Baseline and 4 weeks

Reduction in Daytime Fatigue

To determine if patients with sickle cell disease and nocturnal enuresis receiving desmopressin will have less daytime fatigue compared to the control group.

Time frame: Baseline and 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.